Clinical Trials Browser

Phase 1/2 × Biliary Tract Neoplasms × Paclitaxel × Clear all

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phase 1/2 Recruiting

258 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03314935 2025-08-12

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1/2 Completed

149 enrolled 35 charts

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Phase 1/2 Unknown

20 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Clinical Trials

PETRA

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC